Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTH1R | Q03431 | 7/20 | 0.63 |
| ▸ | GLP1R | P43220 | 6/20 | 0.63 |
| ▸ | NPY1R | P25929 | 1/20 | 0.62 |
| ▸ | NPY2R | P49146 | 1/20 | 0.62 |
| ▸ | NPY4R | P50391 | 1/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.62 |
| ▸ | CALCA | P06881 | 2/20 | 0.61 |
| ▸ | GCGR | P47871 | 1/20 | 0.59 |
| ▸ | GIPR | P48546 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29922398 | 0.92 | GLP1R (0.69) | PTH1RGLP1RCXCR4GCGR | |
| SCHEMBL13734948 | 0.91 | KEAP1 (0.62) | PTH1RGLP1RNPY1RNPY2RNPY4R | |
| SCHEMBL31021136 | 0.91 | GLP1R (0.67) | GLP1RCXCR4GCGRGIPR | |
| SCHEMBL30310773 | 0.91 | GLP1R (0.67) | PTH1RGLP1RCXCR4GCGRGIPR | |
| SCHEMBL30536952 | 0.91 | GLP1R (0.70) | PTH1RGLP1RNPY1RNPY2RNPY4R | |
| SCHEMBL30495604 | 0.90 | GLP1R (0.71) | PTH1RGLP1RNPY1RNPY2RNPY4R | |
| SCHEMBL30750752 | 0.90 | GLP1R (0.73) | GLP1RNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29410247 | 0.89 | NPY1R (0.72) | GLP1RNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL29412272 | 0.89 | CXCR4 (0.66) | GLP1RNPY1RNPY2RNPY4RNPY5R | |
| SCHEMBL30029149 | 0.89 | GLP1R (0.68) | PTH1RGLP1RCXCR4GCGRGIPR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS INC (US) | 2026-04-30 | — | — | US | disclosed |
| US-11504433-B2 | Cholix-derived carriers for oral delivery of heterologous payload | APPLIED MOLECULAR TRANSPORT INC. (US) | 2022-11-22 | — | — | US | disclosed |
| US-20220275029-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | THORNHILL THERAPEUTICS, INC. | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260116928-A1 | COMPOSITIONS AND PARTICLES FOR PAYLOAD DELIVERY | SLC47A2, SLC47A1, SLC39A14 | PTH1R 603/4885GLP1R 671/4885NPY1R 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.